tetano
Editor, Senior Moderator
iScience
. 2023 May 19;26(5):106685.
doi: 10.1016/j.isci.2023.106685. Epub 2023 Apr 20. COVID-19 relapse associated with SARS-CoV-2 evasion from CD4[SUP]+[/SUP] T-cell recognition in an agammaglobulinemia patient
Ryo Morita[SUP] 1 2 [/SUP], Ritsuko Kubota-Koketsu[SUP] 2 [/SUP], Xiuyuan Lu[SUP] 3 [/SUP], Tadahiro Sasaki[SUP] 2 [/SUP], Emi E Nakayama[SUP] 2 [/SUP], Yu-Chen Liu[SUP] 4 [/SUP], Daisuke Okuzaki[SUP] 4 [/SUP], Daisuke Motooka[SUP] 5 [/SUP], James Badger Wing[SUP] 6 [/SUP], Yasunori Fujikawa[SUP] 7 [/SUP], Yuji Ichida[SUP] 8 [/SUP], Kiyoko Amo[SUP] 9 [/SUP], Tetsushi Goto[SUP] 1 [/SUP], Junichi Hara[SUP] 10 [/SUP], Michinori Shirano[SUP] 1 [/SUP], Sho Yamasaki[SUP] 3 [/SUP], Tatsuo Shioda[SUP] 2 [/SUP]
Affiliations
A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4[SUP]+[/SUP] T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4[SUP]+[/SUP] T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.
Keywords: Immunology.
. 2023 May 19;26(5):106685.
doi: 10.1016/j.isci.2023.106685. Epub 2023 Apr 20. COVID-19 relapse associated with SARS-CoV-2 evasion from CD4[SUP]+[/SUP] T-cell recognition in an agammaglobulinemia patient
Ryo Morita[SUP] 1 2 [/SUP], Ritsuko Kubota-Koketsu[SUP] 2 [/SUP], Xiuyuan Lu[SUP] 3 [/SUP], Tadahiro Sasaki[SUP] 2 [/SUP], Emi E Nakayama[SUP] 2 [/SUP], Yu-Chen Liu[SUP] 4 [/SUP], Daisuke Okuzaki[SUP] 4 [/SUP], Daisuke Motooka[SUP] 5 [/SUP], James Badger Wing[SUP] 6 [/SUP], Yasunori Fujikawa[SUP] 7 [/SUP], Yuji Ichida[SUP] 8 [/SUP], Kiyoko Amo[SUP] 9 [/SUP], Tetsushi Goto[SUP] 1 [/SUP], Junichi Hara[SUP] 10 [/SUP], Michinori Shirano[SUP] 1 [/SUP], Sho Yamasaki[SUP] 3 [/SUP], Tatsuo Shioda[SUP] 2 [/SUP]
Affiliations
- PMID: 37124420
- PMCID: PMC10116114
- DOI: 10.1016/j.isci.2023.106685
A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4[SUP]+[/SUP] T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4[SUP]+[/SUP] T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.
Keywords: Immunology.